Loading patent…
AssigneeUniversity of South Florida
InventorsCsilla Ari D'Agostino, Dominic Paul D'Agostino
Estimating the term…
Methods of treating anxiety disorders or reducing anxiety-related behaviors. The methods include administering a therapeutically effective amount of ketone supplementation, such as butanediol, ketone esters (e.g., 1,3-butanediol-acetoacetate diester) and/or ketone salts (e.g., beta-hydroxybutyrate-mineral salt), chronically, sub-chronically, or acutely, with or without admixture with a medium chain triglyceride or in combination. It was determined herein that ketone supplementation reduced anxiety in rats on elevated plus maze as measured by less entries to closed arms, more time spent in open arms, more distance travelled in open arms, and delayed latency to entrance to closed arms, when compared to control. Along with reducing anxiety-related behavior, the chronic, sub-chronic, and acute ketone supplements also caused significant elevation of blood βHB levels and changed blood glucose levels.
A method of treating a patient suffering from an anxiety disorder, comprising orally administering to the patient a therapeutically effective amount of exogenous ketone supplementation chronically, sub-chronically, or acutely, wherein the ketone supplementation comprises a medium chain triglyceride in combination with a beta hydroxybutyrate mineral salt.
A method of reducing anxiety in a patient or subject, comprising administering to the patient or subject a therapeutically effective amount of exogenous ketone supplementation chronically or sub-chronically, wherein the ketone supplementation comprises a medium chain triglyceride in combination with a beta hydroxybutyrate mineral salt.
A method of reducing anxiety in a patient or subject, comprising chronically administering to the patient or subject a therapeutically effective amount of exogenous ketone supplementation, wherein the ketone supplementation includes a ketone salt comprising beta-hydroxybutyrate sodium and/or potassium salt admixed with a medium chain triglyceride in a 1:1 ratio, such that a concentration of the beta-hydroxybutyrate-mineral salt is about 0.4-25 grams of the beta-hydroxybutyrate-mineral salt per kilogram of body weight per day and a concentration of the medium chain triglyceride is about 0.4-25 grams of the medium chain triglyceride per kilogram of body weight per day.
Dependencies are inferred from the claim text.